Member Info for B_Positive

SP target: 0.4p by end of May once offtake is fully announced.

Given AGL is at a £30mcap and GDR has more going for it, at the very least I believe this will be 4-5p by the end of May alone.

They only raised a small amount because of the incoming contracts and revenue growth. Which was a confident display to the market.

2025 a few anticipated developments:

+CE MARK

+FDA APPROVAL

+UK Expansion

+Europe Expansion

+US Expansion

+Middle East Expansion

+New contracts

+Grants

Target: 10-30p, so about 20p a share.

I reckon this will trade 0.4-0.5p again this quarter and do a bigger rise than both VAST and PREM from rock bottom. They both moved up about 300-400%.

+Lower mcap than VAST/PREM

+Much more cash than VAST/PREM

+Significantly higher revenues than VAST/PREM

+Management revamped

+Further orders and offtakes pending

Target 0.5p short term.

Further announcements due on US expansion too:

Another point to remember is that Genedrive is already in collaboration with an as yet unnamed American partner. The deal was struck exactly a year ago:

"Genedrive PLC on Wednesday said it has entered into a clinical trial agreement to support clinical studies to progress the regulatory approval of its MT-RNR1 product. The Manchester, England-based molecular diagnostics company said the deal is with a "leading multi-state physician organisation" based in the US, but did not disclose its name. The partnership will support clinical studies required for engagement with the US Food & Drug Administration." Chief Executive Officer James Cheek said: "I am delighted with this agreement to progress our aim of introduction of our MT-RNR1 point of care pharmacogenetic test to the US. The US is a particularly attractive market for this unique test, given the potential to save hundreds of individuals from life-long deafness and reduce litigation costs relating to the unwanted side effects from antibiotic use on those carrying the gene variant. Additionally, the US market is potentially the most attractive market given its size, birth rates, use of diagnostic testing and reimbursement structure."

https://www.morningstar.co.uk/uk/news/AN_1713976015786175700/genedrive-enters-clinical-trial-deal-in-us-for-mt-rnr1-us-approval.aspx

Given AGL is at a £30mcap and GDR has more going for it, at the very least I believe this will be 4-5p by the end of May alone.

They only raised a small amount because of the incoming contracts and revenue growth. Which was a confident display to the market.

2025 a few anticipated developments:

+CE MARK

+FDA APPROVAL

+UK Expansion

+Europe Expansion

+US Expansion

+Middle East Expansion

+New contracts

+Grants

Target: 10-30p, so about 20p a share.

Drilling about to start shortly. Cap is far too low for it to remain here.

They know they have gold in that area. Just imagine one good drill result.

£100m cap?

Mcap will go to £10-20m before drill results are even out. Far too much potential for it to stay down here.

GGP!!!

GOLD!!!

Mental potential here. Watch it soar

GDR only has 624,895,408 Ordinary Shares. For the small cap space this is absolutely tiny and pittance.

Note Premier African has 50billion in issue and that just 5 bagged on sweet f all.

Therefore 10 bags here with such a low float won't be an issue as it's done many times before from the lows.

Company making year awaits us here.

How it is BS? 5 years ago we saw a rise from 7p to 150p. GDR has set a consistent precedent.

Therefore a move to 10p is an underestimate.

The retail loves this company

The NHS loves this company

The UK Gov loves this company

More love is coming from all through + international Government and companies over the weeks and months ahead.

Given AGL is at a £30mcap and GDR has more going for it, at the very least I believe this will be 4-5p by the end of May alone.

They only raised a small amount because of the incoming contracts and revenue growth. Which was a confident display to the market.

2025 a few anticipated developments:

+CE MARK

+FDA APPROVAL

+UK Expansion

+Europe Expansion

+US Expansion

+Middle East Expansion

+New contracts

+Grants

Target: 10-30p, so about 20p a share.

£1m cash on hand + £1m raise + £500k tax rebate + £Grant cash + revenues = fully funded for 2025.

As for the new contracts, expansions and growth that's coming it's all in the RNS detailing forward plans.

You sound poorly researched.

Anyway, market cap is far too low here. AGL is 3x the market cap and is a one trick pony.

GDR will recreate hard

Fully cashed up for all of 2025. On top of that revenue and contract growth coming.

Investors will happily stomach another raise well above the current share price in 2026, at which point GDR will have much higher revenues and be expanded internationally. With better market conditions in 2026 and with the share price likely in double digits it's all gravy from here.

The market cap should already be about £30MIL or about 5p a share given the progress made.

2025 a few anticipated developments:

+CE MARK

+FDA APPROVAL

+UK Expansion

+Europe Expansion

+US Expansion

+Middle East Expansion

+New contracts

+Grants

Target: 10-30p, so about 20p a share.

Read the RNS and you can see there are these elements coming

+New contracts

+Expansion of existing contracts

+Further revenues to recognise not factored in yet

+Partnership with big players from a position of strength

+Joint Venture

Can't wait to see what else comes this way. So much deep intergration with the big boys.

The IPO was over 5p just a few years ago.

There have been ZERO dilutions since IPO and recently ruled out again.

Can go to 1p quickly which is only a 1/5th of the IPO and demonstrates how undervalued this is.

I think this will return to and exceed the IPO level of 5p.

They've been dug up in the past on the US Government websites, but not sure which parts you have to look.

Interesting. Well we know they are working on new contracts going by what they announced last time. So seems likely to me more are going to drop.

Very likely in fact.

Bring it on!

Looking set to be a real frontrunner for AI cybersecurity.

Read the RNS and you can see there are these elements coming

+New contracts

+Expansion of existing contracts

+Further revenues to recognise not factored in yet

+Partnership with big players from a position of strength

+Joint Venture

Can't wait to see what else comes this way. So much deep intergration with the big boys.

The IPO was over 5p just a few years ago.

There have been ZERO dilutions since IPO and recently ruled out again.

Can go to 1p quickly which is only a 1/5th of the IPO and demonstrates how undervalued this is.

I think this will return to and exceed the IPO level of 5p.

Food for thought: since IPO in 2022, there hasn't been a single placing.

You will be hard pressed to find another small cap that hasn't raised in over 3 years.

This heads back to 5p IPO price in my opinion

Management here is exceptional. No raise/options/warrants, CEO setting an example with his commitments.

It really stands out.